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Summary The relationship between c-erbB-2 gene expression (assessed immunohistochemically), S-phase
fraction (SPF) and prognosis has been analysed in 172 women with primary breast cancer. c-erbB-2 staining
was independent of age, tumour size, number of nodes involved, tumour grade and DNA ploidy, but was
more common in oestrogen receptor (ER) negative tumours (P = 0.02) and progesterone receptor (PgR)
negative tumours (P = 0.03). A weak correlation between c-erbB-2 staining and SPF was observed (r = 0.18).
Amongst women with node negative disease, SPF was significantly related to relapse free survival (RFS,
P = 0.04) while c-erbB-2 staining was not (P = 0.2). In contrast, both SPF (P = 0.002) and c-erbB-2 staining
(P = 0.016) provided significant prognostic information on RFS for women with node positive disease.
Multivariate analysis showed that c-erbB-2 staining and SPF gave independent information on RFS for
women with node positive disease.
Amplification of the c-erbB-2 proto-oncogene occurs in
10-33% of human breast cancers (Slamon et al., 1987;
Venter et al., 1987; Ali et al., 1988). This gene codes for a
185-190 kilodalton transmembrane glycoprotein. The c-
erbB-2 oncogene product can be detected immunohistochem-
ically using formalin-fixed or frozen tissue (Venter et al.,
1987; Barnes et al., 1988; Gusterson et al., 1988; van de
Vijver et al., 1988; Wright et al., 1989; Tandon et al., 1989;
Lovekin et al., 1989; Paik et al., 1989; Dolan et al., 1989).
Over-expression of the c-erbB-2 oncoprotein has been
reported to be associated with a shorter relapse free survival
(RFS) and survival for breast cancer patients, particularly
those with axillary node positive disease (Venter et al., 1987;
Barnes et al., 1988; Gusterson et al., 1988; van de Vijver et
al., 1988; Wright et al., 1989; Tandon et al., 1989; Lovekin et
al., 1989; Paik et al., 1989; Dolan et al., 1989; Slamon et al.,
1989; Borg et al., 1989). As the c-erbB-2 oncogene product
has a structure highly homologous to that of the epidermal
growth factor receptor (Akiyama et al., 1986; Yamamoto et
al., 1986), it has been postulated that over-expression of this
protein might be associated with faster tumour proliferation.
In this study we have examined the relationship between
c-erbB-2 expression and tumour proliferation, measured by
estimating the proportion of cells in the S-phase of the cell
cycle using DNA flow cytometry. In previous studies, we and
others have shown high S-phase fraction (SPF) to be an
indicator of poor prognosis both in node negative and node
positive breast cancer (O'Reilly et al., 1990a; O'Reilly et al.,
1990b). By examining both c-erbB-2 expression and SPF we
have been able to assess whether these two features of the
tumour give independent prognostic information.
Methods
Patients
The case records of 172 patients with primary operable
breast cancer diagnosed between 1980 and 1983 were re-
viewed. All patients had had total mastectomy and axillary
clearance or a conservation technique comprising excision
biopsy and axillary clearance followed by iridium implanta-
tion and external beam radiotherapy as primary treatment.
Fifteen patients received adjuvant CMF chemotherapy.
Tumour size, measured clinically, was recorded for all cases.
Steroid hormone receptor status was determined using a
dextran-coated charcoal ligand binding assay (King et al.,
1979), with a value of > 10 fmol mg-' cytosol protein taken
as positive. Data on oestrogen receptor (ER) status were
available for 157 tumours and on progesterone receptor
(PgR) status for 156 tumours. The histological type of all
tumours at diagnosis was documented and infiltrating ductal
carcinomas were graded by one pathologist using the criteria
of Bloom and Richardson (1957).
DNAflow cytometry
Flow cytometric DNA analysis had been successfully per-
formed on tissue from all patients as part of a larger study.
Cell suspensions prepared from 50 sm sections cut from
formalin-fixed paraffin embedded tissue from the primary
tumour were processed as described previously (O'Reilly et
al., 1990b). At least 10,000 cells were scanned to construct
each histogram. A histogram was considered interpretable if
the coefficient of variation was less than or equal to 8%. The
DNA index was calculated by measuring the position of any
aneuploid Gl peak relative to the normal GI/GO peak, with
a DNA index of 1.0 indicating the presence of only diploid
cells. For DNA diploid tumours, the proportion of cells in
S-phase was calculated by the method of Baisch et al. (1975).
For aneuploid tumours with a DNA index > 1.2 a
modification of this method was used to calculate the S-
phase fraction for the aneuploid cells alone (Camplejohn et
al., 1989).
Immunohistochemistry
Staining was assessed on 3 lm sections cut from formalin-
fixed, paraffin-embedded tissue as described previously (Bar-
nes et al., 1988). Briefly, sections were incubated overnight at
4°C with a 3 1tg ml-' solution of affinity purified polyclonal
antibody 21N (kindly supplied by Dr W.J. Gullick, Hammer-
smith Hospital) raised in rabbits to the predicted amino acid
sequence from residues 1243-1255 ofc-erbB-2 (Gullick et al.,
1987). Sections were then treated with biotinylated swine
anti-rabbit immunoglobulin at 1:500 dilution followed by
avidin-biotin peroxidase complex for 30 min. Peroxidase
activity was demonstrated using diamino-benzidine solution
and the nuclei were counterstained with haematoxylin. Stain-
ing was scored by assessing the proportion of cells staining
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(0%, 1-20%, 21-80%, 81-100%) and the intensity of stain-
ing (weak (+), moderate (+ +) or strong (++ +)). All
cases were reviewed by two observers.
Statistical analysis
Relationships between variables were examined using the Chi
squared test, the Mann-Whitney non-parametric test and the
Pearson correlation coefficient. Relapse free survival and sur-
vival curves were calculated using the method of Kaplan and
Meier (Peto et al., 1977) and differences between curves were
analysed by the logrank test. Multivariate analysis was per-
formed using the Cox proportional hazards model (Cox,
1972).
Results
Thirty-nine of the 172 tumours (23%) showed some degree of
tumour cell membrane staining for the c-erbB-2 product.
There was a close correlation between intensity of staining
and percentage of cells stained (r = 0.92). Twenty-eight tu-
mours (16%) had moderate or strong staining of more than
20% of cells and were regarded as c-erbB-2 positive. The
remaining 144 tumours, which exhibited either no staining or
weak staining, were classified as c-erbB-2 negative.
The relationship between c-erbB-2 immunostaining and
other tumour characteristics is shown in Table I. c-erbB-2
positive tumours were significantly more likely to be ER
negative (P = 0.02) and PgR negative (P = 0.03) than c-erbB-
2 negative tumours. No association was observed between
c-erbB-2 staining and tumour size, grade, nodal status, or
DNA ploidy.
S-phase fraction (SPF) could be measured for 153/172
(87%) tumours, with a median value of 8% (range
1.1-35%). There was a significant association between c-
erbB-2 staining and an SPF above the median using Chi-
squared analysis (P = 0.003). In addition, the median SPF of
c-erbB-2 positive tumours was significantly higher then the
median SPF of c-erbB-2 negative tumours (10.5 vs 7.9,
P = 0.02). However, the correlation coefficient between c-
erbB-2 staining and SPF was only 0.18 showing this to be a
weak association.
There was no significant difference in relapse free survival
(RFS) between patients with c-erbB-2 negative tumours and
those with c-erbB-2 positive tumours (P = 0.2). While there
was a trend for patients with c-erbB-2 positive tumours to
have a shorter survival, this did not achieve statistical
significance (P = 0.08). The influence of c-erbB-2 on outcome
was then examined within subgroups defined by nodal status.
Table I Relationship between c-erbB-2 staining and other prognostic
factors
Factor c-erbB-2 positive P value
Tumour size
< 2 cm 10/65 (15%)
>2cm 18/107 (17%) 0.97
Tumour grade
Grade 1 or 2 12/89 (13%)
Grade 3 15/60 (25%) 0.12
Nodal status
Negative 11/87 (13%)
Positive 17/85 (20%) 0.42
1 -3 nodes 9/49 (18%)
> 4 nodes 8/36 (22%) 0.86
Steroid receptor status
ER negative 10/33 (33%)
ER positive 15/124 (12%) 0.02
PgR negative 16/67 (24%)
PgR positive 9/89 (10%) 0.03
Tumour ploidy
Diploid 5/57 (9%)
Aneuploid 23/115 (20%) 0.1
S-phase fraction
Low (below median) 5/77 (6%)
High (above median) 19/75 (25%) 0.003
c-erbB-2 staining did not influence either RFS (P = 0.2) or
survival (P = 0.8) for patients with node negative breast
cancer. However, patients with node positive disease whose
tumours were also c-erbB-2 positive had both a shorter RFS
(Figure 1) and survival (Figure 2) than those with c-erbB-2
negative tumours. In contrast, high SPF was an indicator of
poor prognosis in both node negative (RFS P = 0.04;
S P = 0.05) and node positive (RFS P = 0.002; S P = 0.02)
disease.
Multivariate analysis was performed to assess the inde-
pendence of the prognostic information given by c-erbB-2
staining and SPF in node positive breast cancer. This showed
that the number of positive axillary nodes was the most
powerful predictor of both RFS (P = 0.001) and survival
(P = 0.01). However, both c-erbB-2 staining (P = 0.02) and
SPF (P = 0.03) were significant independent prognostic vari-
ables for RFS, but not for survival.
Discussion
There have been a number of conflicting reports of the
relationship between c-erbB-2 amplification or expression and
other pathological features of human breast cancer (Slamon
et al., 1987; Venter et al., 1987; Ali et al., 1988; Barnes et al.,
1988; Gusterson et al., 1988; van de Vijver et al., 1988;
Wright et al., 1989; Tandon et al., 1989; Lovekin et al., 1989;
Paik et al., 1989; Dolan et al., 1989; Slamon et al., 1989;
Borg et al., 1989; Zhou et al., 1987). An association has been
reported between c-erbB-2 expression and large tumour size
in only two studies (van de Vijver et al., 1988; Borg et al.,
1989). A significant association between c-erbB-2 expression
and poorly differentiated tumours has been demonstrated in
some studies (Barnes et al., 1988; Wright et al., 1989;
Lovekin et al., 1989) but not in others (van de Vijver et al.,
1988; Zhou et al., 1987). Similarly, the inverse relationship
noted in some studies between c-erbB-2 expression and ster-
oid receptor status (Wright et al., 1989; Tandon et al., 1989;
Lovekin et al., 1989; Zhou et al., 1987) has not been univer-









Figure 1 Relapse free survival curves for node positive breast
cancer: Patients with c-erbB-2 positive tumours vs patients with
c-erbB-2 negative tumours.
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Figure 2 Survival curves for node positive breast cancer:
patients with c-erbB-2 positive tumours vs patients with c-erbB-2
negative tumours.446 S.M. O'REILLY et al.
other report analysing the relationship between c-erbB-2 ex-
pression and DNA ploidy measured by flow cytometry (Borg
et al., 1989) found no significant association. In the current
analysis, steroid receptor status was the only one of these
factors significantly associated with c-erbB-2 status.
As the c-erbB-2 oncogene product has a structure highly
homologous to that of the epidermal growth factor receptor
(Akiyama et al., 1986; Yamamoto et al., 1986), it has been
postulated that over-expression of this protein might be
associated with faster tumour proliferation. In this study, a
statistically significant association was observed between c-
erbB-2 expression and high SPF using both Chi-squared and
non-parametric analysis. However, these tests do not estimate
the proportion of variability in one factor attributable to its
relationship with the other. Such an estimate is, however,
obtained by squaring the correlation coefficient. Our results,
with a correlation coefficient of 0.18, suggest that less than
5% of the variability in SPF is due to its association with
c-erbB-2. Borg et al. (1989), in the only other report examin-
ing the relationship between SPF and c-erbB-2 expression in
infiltrating tumours, found a highly significant (P=0.0001)
association between c-erbB-2 and high SPF using Chi-
squared analysis, but did not report a correlation coefficient.
Their report also found c-erbB-2 to be significantly associated
with nodal status, tumour size, clinical stage, ER status and
PgR status in addition to SPF.
The relationship between the c-erbB-2 oncogene and prog-
nosis for patients with breast cancer has now been examined
in a number of studies. These have related both gene
amplification (Slamon et al., 1987; Zhou et al., 1987; Ali et
al., 1988; Slamon et al., 1989) and over-expression of the
oncogene product (Venter et al., 1987; Barnes et al., 1988;
Gusterson et al., 1988; van de Vijver et al., 1988; Wright et
al., 1989; Tandon et al., 1989; Lovekin et al., 1989; Paik et
al., 1989; Dolan et al., 1989; Slamon et al., 1989; Borg et al.,
1989) to clinical outcome. While some studies have not found
an association between c-erbB-2 and poor prognosis (Barnes
et al., 1988; van de Vijver et al., 1988; Gusterson et al.,
1988), recent large studies, each including more than 500
patients, have demonstrated a correlation between c-erbB-2
and both shorter relapse free survival and survival (Slamon
et al., 1989; Tandon et al., 1989; Lovekin et al., 1989). Two
studies have reported that the prognostic significance of c-
erbB-2 is confined to patients with node positive breast
cancer (Slamon et al., 1989; Tandon et al., 1989). Our report
confirms the association between c-erbB-2 staining and poor
prognosis for patients with node positive disease. In addition,
multivariate analysis shows that, while the number of axillary
nodes containing tumour deposits is the most powerful pre-
dictor of relapse free survival, c-erbB-2 expression and SPF
give additional independent significant prognostic inform-
ation.
The mechanism of action by which expression of the c-
erbB-2 oncoprotein leads to a poor prognosis remain uncer-
tain. We found no significant relationship between c-erbB-2
expression and tumour burden, as measured by tumour size
or the number of nodes involved. One possibility would be
that c-erbB-2 expression is associated with resistance to
chemotherapy or endocrine therapy. In this study, the associ-
ation of c-erbB-2 expression with both shorter RFS and
survival does not, however, support this hypothesis. Our
results, albeit on a relatively small number of patients, also
suggest that c-erbB-2 expression contributes little to the pro-
liferative activity of the primary tumour. Further studies are
required to assess the relationship between c-erbB-2 and pro-
liferative activity in metastases.
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